Discover 1,917 paid clinical trials in Arlington, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,917
First In Human Study of CX-2051 in Advanced Solid Tumors
for
Solid Tumor, Adult
Location: Fort Worth TX, San Antonio TX, Denver CO, Nashville TN,
Sponsor: CytomX Therapeutics
Sex: All
Age: 18+
Code: NCT06265688
Phase1, Recruiting
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
for
Throat Carcinoma
Location: Fort Worth TX, Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT04003051
Phase2, Recruiting
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
for
Amblyopia
Location: Fort Worth TX, Crestview FL, Indianapolis IN,
Sponsor: Luminopia
Sex: All
Age: 0+
Code: NCT06429280
Recruiting
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
for
Amblyopia
Location: Fort Worth TX, Oklahoma City OK, Houston TX,
Sponsor: Jaeb Center for Health Research
Sex: All
Age: 3 - 13
Code: NCT04378790
Phase3, Recruiting
New
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Location: Fort Worth TX, Dallas TX, Tyler TX, Abilene TX,
Sponsor: Genmab
Sex: All
Age: 18+
Code: NCT05579366
Phase1, Phase2, Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Fort Worth TX, Austin TX, San Antonio TX, Tulsa OK,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06824467
Phase3, Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
for
Endometrial Cancer
Location: Fort Worth TX, Austin TX, San Antonio TX, Tulsa OK,
Sponsor: Kartos Therapeutics, Inc.
Sex: Female
Age: 18+
Code: NCT05797831
Phase2, Phase3, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
for
Cervical Cancer
Location: Fort Worth TX, Tyler TX, Shreveport LA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT07216703
Phase3, Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
for
Solid Cancer
Location: Fort Worth TX, Oklahoma City OK, Houston TX, Tulsa OK,
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT06161025
Phase2, Phase3, Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
for
Endometrial Cancer
Location: Fort Worth TX, Tyler TX, Shreveport LA, Houston TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06952504
Phase3, Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
for
Mesothelioma, Non Small Cell Lung Cancer,
Location: Fort Worth TX, Dallas TX, Tyler TX, Houston TX,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT05245500
Phase1, Recruiting
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
for
Endometrioid Endometrial Cancer
Location: Fort Worth TX, Dallas TX, Tucson AZ, Greenville SC,
Sponsor: Traws Pharma, Inc.
Sex: Female
Age: 18+
Code: NCT05705505
Phase1, Phase2, Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
for
Ovarian Cancer Recurrent
Location: Fort Worth TX, Oklahoma City OK, Shreveport LA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06843447
Phase1, Phase2, Recruiting
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)